Comparative Pharmacology
Head-to-head clinical analysis: NEMBUTAL SODIUM versus SODIUM PENTOBARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEMBUTAL SODIUM versus SODIUM PENTOBARBITAL.
NEMBUTAL SODIUM vs SODIUM PENTOBARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing neuronal inhibition. Depresses the reticular activating system at higher doses.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing inhibitory neurotransmission. At high doses, it acts as a GABA mimetic and depresses neuronal excitability.
30 mg IV or IM every 6 to 8 hours as needed for sedation; 65 to 100 mg IV or IM for hypnosis; 200 to 500 mg IV or IM for anticonvulsant effect in status epilepticus. Maximum single dose 500 mg.
IV: 100-150 mg administered over 1-2 minutes for induction of anesthesia; for seizure control, 100 mg IV every 5-10 minutes up to 500 mg. For maintenance of anesthesia, 50 mg IV as needed every 15-30 minutes. IM: 150-200 mg for preoperative sedation.
None Documented
None Documented
Terminal elimination half-life: 15-40 hours in adults; clinically relevant for accumulation with repeated dosing, especially in hepatic impairment.
15-50 hours (dose-dependent; prolonged in hepatic impairment).
Renal: ~25% unchanged; hepatic metabolism to inactive metabolites; ~50% excreted as metabolites in urine; biliary/fecal: minor.
Renal (25-50% unchanged); hepatic metabolism to inactive metabolites; fecal <5%.
Category C
Category D/X
Barbiturate
Barbiturate